[Effect of tongxinluo capsule on plasma endothelin and calcitonin gene related peptide in patients with unstable angina pectoris]

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in this randomized controlled trial publication.

To investigate the effect of Tongxinluo capsule (TXLC) on the patients with unstable angina pectoris (UAP).

Who Took Part

The study group was 20 subjects.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Patients of UAP were divided into two groups, the treated group (n = 60) was treated with TXLC and the Danshen group (n = 30) was treated with composite Danshen tablet.

The plasma endothelin (ET) and calcitonin gene related peptide (CGRP) were measured before and after treatment.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

Data were compared between the two groups and also compared with those measured in 20 healthy subjects for control.

What Was Measured

The subject headings attached to it are Angina, Unstable, Calcitonin Gene-Related Peptide, Capsules, Drugs, Chinese Herbal, Endothelins and Phytotherapy.

What This Means in Plain Language

The paper is a randomized study of CGRP (Calcitonin Gene-Related Peptide) in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2002 (Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine), a journal based in China.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.